After two years of strong gains, smallcap stocks fell sharply in 2025, but the correction may be setting up opportunities for long-term investors.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
This is a good opportunity for long-term investors to pick quality small and midcap stocks at reasonable valuations.
An acute drug shortage in the US and stable pricing along with product launches are likely to boost revenues of India's pharmaceutical companies during the first quarter of this financial year, analysts said. Most brokerages estimate a top line growth of around 14-15 per cent, with earnings before interest, taxes, depreciation, and amortisation (Ebitda) growth of 24-30 per cent for Q1 of FY24. Hospitals are, however, likely to report lower occupancy rates, and diagnostics companies may witness an impact from delayed monsoon.
Domestic firms Aurobindo Pharma, Glenmark Pharmaceuticals and Natco Pharma have received US health regulator's approval to market their generic Rizatriptan Benzoate orally disintegrating tablets used for treating migraine in the American market.
10 non-bank and non-finance stocks from the BSE500 Index universe that offer an optimal blend of low valuation, reasonably robust revenue and earnings growth in recent quarters, a strong balance sheet, and most importantly, positive cash flow from their operations.
The plan is to issue CLs for Trastuzumab (or Herceptin, used for treating breast cancer), Ixabepilone (used for chemotherapy in breast cancer treatment) and Dasatinib (or Sprycel, for leukaemia).
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.
Bayer will not accept a ruling by the Intellectual Property Appellate Board in Chennai on Monday, upholding the compulsory licence granted on March 9 last year and it will appeal against the patent office order at the high court in Mumbai, a spokesperson told PTI.
Natco Pharma's anti-cancer drug, NRC-AN-019, has received 'Orphan Drug' designation from the US Food and Drug Administration (USFDA) for three indications - glioma (brain tumour), pancreatic cancer and chronic myelogenous leukemia.
The company has sought the United States Food and Drug Administration (FDA)'s approval to market a generic version of Tamiflu (oseltamivir phosphate), said Gilead Sciences, the US company that owns the Tamiflu patent. Natco officials declined to comment on the development.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The drugs manufacturing industry is on a state of alert following two landmark developments over a cancer treatment medicine.
Natco Pharma has opposed an application made by Novartis India to the controller of patents, for grant of a patent for an anti-cancer drug 'Imatinib Mesylate'.
Natco Pharma has announced the launch of a new generation anti-migraine drug under the brand name 'Ritza'.
Services attracted the most FDI during the first eleven months period of 2015-16.
The BSE Midcap also cut all its intraday gains to shed 0.3% at close
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Shanghvi needs to deploy this excess cash.
Analysts attribute this outperformance to the government's proactive economic reform measures
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Delegation visit ahead of patent law report.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
The S&P BSE Midcap and the S&P BSE Smallcap indices gained 0.3% and 0.5%, respectively
Metal stocks were trading under pressure while IT, auto, realty stocks gained in today's deals
Investor wealth too fell by nearly Rs 7 lakh crore during 2015-16 or over Rs 2,700 crore per trading session.
The S&P BSE Sensex ended the session at 25,342, up 3 points while the Nifty50 closed at 7,738 points.
V-Mart, Manaksia, Whirlpool Global and few other companies posted better third-quarter results.
The Supreme Court had rejected the company's plea for a patent on cancer drug Glivec in April.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis
Investors indulged in profit booking at attractive and higher valuations
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The Sensex closed down 308 points at 24,894 and the Nifty has lost 96 points at 7,559.
The S&P BSE Sensex ended down 371 points at 24,966 and the Nifty50 closed 101 points lower at 7,615.
India had been engaged in a contentious battle with the US over the issue, especially in the pharmaceutical sector.
The 30-share Sensex ended down by 59 points at 27,027 and the 50-share Nifty slipped 7 points at 8,087.
Indian firm to soon launch copycat of anti-breast-cancer drug.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances